Novel nanostructure-coupled biosensor platform for one-step high-throughput quantification of serum neutralizing antibody after COVID-19 vaccination

Liping Huang,Ying Li,Changyou Luo,Youqian Chen,Nadia Touil,Hicham-El Annaz,Shaoqi Zeng,Tang Dang,Jiawei Liang,Wenjun Hu,Hao Xu,Jiasheng Tu,Lin Wang,Yan Shen,Gang L Liu,Gang L. Liu
DOI: https://doi.org/10.1016/j.bios.2021.113868
IF: 12.545
2022-03-01
Biosensors and Bioelectronics
Abstract:COVID-19 vaccination efficacy depends on serum levels of the neutralizing antibodies (NAs) specific to the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Therefore, a high-throughput rapid assay capable of measuring the total SARS-CoV-2 NA level is urgently needed for COVID-19 serodiagnosis, convalescent plasma therapy, vaccine development, and assessment. Here, we developed a novel nanoplasmonic immunosorbent assay (NanoPISA) platform for one-step rapid quantification of SARS-CoV-2 NAs in clinical serum samples for high-throughput evaluation of COVID-19 vaccine effectiveness. The NanoPISA platform enhanced by the use of nanoporous hollow gold nanoparticle coupling was able to detect SARS-CoV-2 NAs with a limit of detection of 0.2 pM within 15 min without washing steps. The one-step NanoPISA for SARS-CoV-2 NA detection in clinical specimens yielded good results, comparable with those obtained in the gold-standard seroneutralization test and the surrogate virus-neutralizing enzyme-linked immunosorbent assay. Collectively, the one-step NanoPISA might be a rapid and high-throughput NA-quantification platform for evaluating the effectiveness of COVID-19 vaccines.
biotechnology & applied microbiology,biophysics,chemistry, analytical,electrochemistry,nanoscience & nanotechnology
What problem does this paper attempt to address?